| First Author | Chao J | Year | 1997 |
| Journal | Trends Cardiovasc Med | Volume | 7 |
| Issue | 8 | Pages | 307-11 |
| PubMed ID | 21235901 | Mgi Jnum | J:44524 |
| Mgi Id | MGI:1100408 | Doi | 10.1016/S1050-1738(97)00089-3 |
| Citation | Chao J, et al. (1997) Kallistatin in blood pressure regulation transgenic and somatic gene delivery studies. Trends Cardiovasc Med 7(8):307-311 |
| abstractText | Kallistatin, first discovered as a human kallikrein- binding protein in the circulation shares high homology with other plasma serine proteinase inhibitors (serpins). It forms a covalently linked complex with tissue kallikrein and inhibits kallikrein's activity. Substantial evidence has accumulated in recent years indicating that kallistatin may play a role in blood pressure regulation independent of its interaction with tissue kallikrein. Intravenous injection of kallistatin into rats and mice results in a rapid and transient reduction of blood pressure in a dose-dependent manner Functional analysis in transgenic mice overexpressing rat kallikrein-binding protein an analogue of human kallistatin, revealed that these mice have significantly lower blood pressure compared with control littermates. Adenovirus-mediated delivery of the human kallistatin gene can cause significant blood pressure reductions for 4 weeks in spontaneously hypertensive rats. Finally, kallistatin can induce vasorelaxation in isolated rat aortic rings and reduce renal perfusion pressure in the isolated perfused kidney. Together these findings suggest a direct role for kallistatin in regulating blood pressure and raise the possibility for the development of new pharmacological treatments for hypertension. (C) 1997, Elsevier Science Inc. |
